Agregátor RSS

V na pohled obyčejné klávesnici je ukrytý celý počítač i s akumulátorem • Uvnitř můžete vyměnit i paměti, nejen pevný disk • Chytrě vymyšlený USB-C hub schováte za monitor

AI actress Tilly Norwood went viral after glitching into Chinese on Piers Morgan Uncensored last night. Her "Talking Tilly" video call service face-scans every caller for an 18+ age check, senses callers' moods during calls, and shuts down permanently on September 27. We tried it and read the fine print. [...]

AI actress Tilly Norwood went viral after glitching into Chinese on Piers Morgan Uncensored last night. Her "Talking Tilly" video call service face-scans every caller for an 18+ age check, senses callers' moods during calls, and shuts down permanently on September 27. We tried it and read the fine print. [...]

Detektory textů umělé inteligence často selhávají a pracují s pravděpodobností • Nastavený rozhodovací práh zásadně ovlivňuje celkovou míru falešných poplachů • Systém Pangram vykázal nejvyšší přesnost i nejlepší ekonomickou výhodnost

SolarWinds has released security updates to address a high-severity flaw in Access Rights Manager (ARM) that, if successfully exploited, could lead to an unauthenticated remote code execution vulnerability. The vulnerability, tracked as CVE-2026-28326, is rated 8.8 out of 10.0 on the CVSS scoring system. The issue affects all versions of Access Rights Manager 2026.2 and prior. "SolarWinds Ravie Lakshmananhttp://www.blogger.com/profile/[email protected]

Do předběžného přístupu vstoupila nová česká hra od Bohemia Interactive s názvem Cosmo Tales. A to je tak ta poslední celkem rozumně znějící věta, kterou o tomto počinu lze říct.

A critical vulnerability impacting Orkes Conductor is being actively exploited in the wild, according to Fortinet. The vulnerability in question is CVE-2026-58138 (CVSS v3.1 score: 9.8/CVSS v4 score: 9.3), which relates to a case of unauthenticated remote code execution. "Orkes Conductor 3.21.21 before 3.30.2 contains an unauthenticated remote code execution vulnerability that allows remote Ravie Lakshmananhttp://www.blogger.com/profile/[email protected]

Google's Gemini model has become the latest artificial intelligence (AI) system to access the internet and break into other companies during a cybersecurity evaluation. The development was first reported by The Wall Street Journal. The incidents occurred in May 2026 as part of a test run conducted by Israeli company Irregular. The evaluation partner was also involved in similar hacks disclosed Ravie Lakshmananhttp://www.blogger.com/profile/[email protected]

Navazujeme na téma, jak se může mladý člověk naučit programovat. • Neprogramátor tvořící s AI napsal dopis dánskému vývojáři Seemannovi. • Následovala diskuze s mnoha zajímavými názory.

An attacker copied about 170 of CrowdSec's private GitHub repositories on May 22 using the account of an employee who had just left, CrowdSec said on September 18. The French security company had kept his GitHub access open. CrowdSec says his laptop was compromised in May's supply chain attack on TanStack, in which malicious versions of TanStack's npm packages stole credentials from Swati Khandelwalhttp://www.blogger.com/profile/[email protected]

The U.S. Cybersecurity and Infrastructure Security Agency (CISA) on Friday added three security flaws impacting the Linux kernel to its Known Exploited Vulnerabilities (KEV) catalog, citing evidence of active exploitation. The vulnerabilities are listed below - CVE-2025-39682 (CVSS score: 9.8) - An improper check for unusual or exceptional conditions vulnerability in the TLS receive path Ravie Lakshmananhttp://www.blogger.com/profile/[email protected]

Konec září je ideální chvíle projít domácí rozpočet a podívat se, kde se dá rozumně ušetřit. Tentokrát jsme vybrali akce, které pokrývají běžné výdaje od drogerie a kosmetiky přes kuchyňské spotřebiče až po mobilní tarif, streaming nebo data na cesty. Většina z nich platí jen do konce měsíce, některé dokonce jen pár dní.

Počítačová hra Factorio (Wikipedie) nově běží nativně na ARM64 Linuxu a headsetu Steam Frame.

The system, designed by Stanford researchers, identified which drugs are more likely to succeed in trials and even proposed a cancer treatment a major drugmaker later landed on too.

Developing a new drug can take years and cost hundreds of millions of dollars, and even then, most candidates ultimately fail. Now, researchers at Stanford have built a virtual biotech company with 37,000 AI agents that work together to analyze drug targets and design therapies.

Roughly 90 percent of drugs that enter clinical trials never reach the market. That’s often because promising results in the lab don’t translate to patients, or the drug causes dangerous side-effects not caught earlier in the development process.

Part of the problem is the evidence that could help catch these issues earlier in the process is scattered across disciplines and formats, making it hard for any single team to weigh it all.

To get around this, a Stanford team created a system they call a virtual biotech, which consists of up to 37,000 AI agents built to mimic the divisions of a real drug-development company. In a paper published in Science, the system identified which types of drug targets are more likely to succeed in clinical trials and even proposed a lung cancer treatment that a major drugmaker later landed on too.

“Our idea was to see how far we could push this. Could we create a biotech company that takes on everything from looking for drug targets all the way to designing clinical trials?” senior author James Zou said in a press release.

The new system features a virtual chief scientific officer (CSO) that takes a query from a human user and then delegates tasks to an army of specialized “scientist” agents working on the problem.

These agents are armed with their own databases and tools and are split into one of four divisions that specialize in finding and validating drug targets, assessing safety risks, choosing how a drug should be delivered, and reviewing existing clinical trial data. The system has built-in access to the Open Targets database, a massive public repository of clinical trial data.

To test the system, the researchers gave it an existing study showing that genetic evidence can help predict which drugs succeed in trials and asked it how to build on that research. The CSO decided the first step was to improve the quality of the data it had access to because many trials in the Open Targets database don’t clearly record whether the drug actually worked.

So, it asked its researcher agents to dig through the outcomes of 37,075 individual Phase II and III trials, assigning one agent to each trial. The agents searched trial registries, published papers, and press releases for results. They crunched through the job in about six hours—a fraction of the time it would take a team of humans.

The CSO asked another agent to look for promising gene candidates by scouring a public database of human tissues showing which genes are switched on in which cell types. It came up with a two-part scoring system, which first measured whether a gene was active in just one type of cell or across many and then gauged whether its activity was controlled more like an on-off switch or could be dialed up and down like a dimmer switch.

Comparing those scores to the updated trial outcome data revealed a pattern. Drugs aimed at switch-like genes only found in a small number of cell types were 48 percent more likely to eventually reach the market, 40 percent more likely to advance from Phase 1 to Phase 2 trials, and had 32 percent fewer adverse events than drugs hitting more broadly active targets.

The researchers then pushed the system further, asking it to evaluate a protein called B7-H3 that’s associated with lung cancer. The agents discovered the protein was particularly common in connective-tissue cells called fibroblasts that are often found close to tumor cells.

The agents then discovered evidence those cells were suppressing the activity of nearby immune cells, preventing the body from detecting and reacting to the tumors. The system proposed a therapy that would tag cells expressing B7-H3 with an antibody to help direct a toxic chemotherapy drug to them.

The virtual biotech came up with its solution based solely on data available before January 2025, but in August of that year a major pharmaceutical company arrived at the same strategy independently, when its B7-H3-targeted therapy ifinatamab deruxtecan received FDA breakthrough therapy status. “This was really exciting as an independent, third-party validation that’s consistent with the effects and the design proposed by the virtual biotech,” Zou said.

However, coming up with drug targets is just one step in a long, expensive drug discovery process. While refining the candidate selection process could prevent drug companies from pursuing some obvious dead ends, it can’t speed up the rigorous lab testing and clinical trials required to get a drug to market.

Nonetheless, given the industry’s woeful record at translating promising science into finished products, an army of AI scientists that can significantly speed up a critical part of the drug discovery pipeline could be just what the doctor ordered.

The post Virtual Biotech Company Puts 37,000 AI Agents to Work on Drug Discovery appeared first on SingularityHub.

Ucelený přehled článků, zpráviček a diskusí za minulých 7 dní.

Jak se zdá, oxid uhličitý nemusí být jen nechtěný plynem, který se snažíme dostat z atmosféry. Tým Yale University ho dokázal s využitím plazmatu a elektřiny přimět k produkci užitečných chemických látek, včetně složitějších produktů, jako je metanol nebo butan. Stane se z oxidu uhličitého zajímavá surovina?

Dá se přehlédnout 1000 proteinů důležitých pro funkce mozku? Pokud jsou dost malé, pak ano. Co má vlastně v naší hlavě na starosti „temná hmota“ proteomu?

Fyzikům dlouho unikaly kvantové skoky fononů, i když byly předpovězeny už od počátku 20. století. Nakonec uspěl tým, který vedl Amir Safavi-Naeini ze Stanfordu. V reálném čase pozorovali kvantové skoky zvuku v mechanickém rezonátoru, odečítané propojeným supravodivým qubitem.